Next Article in Journal
Metabolic Pathways, Enzymes, and Metabolites: Opportunities in Cancer Therapy
Previous Article in Journal
Evaluation of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma Using Clinical-Ultrasound Radiomic Machine Learning-Based Model
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 14
Issue 21
10.3390/cancers14215267
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Pathologic Predictors of Response to Treatment of Immune Checkpoint Inhibitor–Induced Kidney Injury

Cancers 2022, 14(21), 5267; https://doi.org/10.3390/cancers14215267
by Ala Abudayyeh 1,*, Liye Suo 2, Heather Lin 3, Omar Mamlouk 1, Noha Abdel-Wahab 4,5,6 and Amanda Tchakarov 2,*
Reviewer 1:
Kamal Kant Sahu
Reviewer 2: Anonymous
Cancers 2022, 14(21), 5267; https://doi.org/10.3390/cancers14215267
Submission received: 26 September 2022 / Revised: 22 October 2022 / Accepted: 22 October 2022 / Published: 27 October 2022
(This article belongs to the Section Cancer Immunology and Immunotherapy)

Round 1

Reviewer 1 Report

A well-written paper discussing real-world experience.  Immune-related side effects are common and need close attention to etiology and intervention

Minor comments

-Most patients responded to steroids and had grade II-III toxicity. Please explain why re-challenging was done only in 17% of the patients.

- Did the occurrence of renal toxicity affect the survival? I think the authors can easily compare this with the patients who received ICI with developing nephritis.

-https://pubmed.ncbi.nlm.nih.gov/33912752/ à This paper discusses the ICI-AKI with non-ICI AKI. Can we include serum CRP and uRBP/Cr in our patient cohort?

- What was the median duration of these patients on steroid therapy?

-Please add a PRISMA diagram

 

 

Author Response

Please see attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

Author’s data pathologic evaluation of ICI-induced AIN showed that the degree of fibrosis (i.e., IFTA) is associated with renal response within 3 months of initiating treatment, and that renal response and use of concurrent ICIs was associated with better OS in these patients. Given the widespread use of ICIs in cancer treatment, further studies are needed to identify novel biomarkers of risk for and effective early intervention and treatment of ICI-induced AIN to improve both renal outcomes and OS in these patients.

This is a very meaningful study, and I have a few little suggestions:

First, as a general comment, we suggest that the authors increase the sample size in future studies.

In the result part, the resolution of the author's figures are not enough, and it will be distorted when enlarged, especially the texts on the figures are not clear.

In the discussion section, we suggest to further discuss the significance of this study compare with the current related research. In fact, the author's discussion section is short and cannot highlight the characteristics and advantages of the study.

Author Response

Please see attachment

The figures have been created with higher resolution as a PDF file but unable to upload since system only allows one document to be uploaded.

Author Response File: Author Response.pdf

Back to TopTop